Feature Channels: Diabetes

Filters close
access_time Embargo lifts in 2 days
This news release is embargoed until 24-Nov-2024 10:00 AM EST Released to reporters: 20-Nov-2024 6:20 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 24-Nov-2024 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 20-Nov-2024 3:45 PM EST
More Than Half of U.S. Adults Could Benefit From GLP-1 Medications, Researchers Find
Beth Israel Lahey Health

In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) estimated that 137 million U.S. adults, more than half of all adults, are eligible for semagludtide for weight loss, diabetes management, or prevention of recurrent cardiovascular events.

Newswise: 1920_stroke-guidelines-healthy-diet-cedars-sinai.jpg?10000
Released: 20-Nov-2024 10:35 AM EST
Updated Stroke Guidelines Focus on Women, Medications
Cedars-Sinai

Newly updated stroke prevention guidelines from the American Heart Association and American Stroke Association say women with endometriosis and women with early-onset menopause are at greater risk.

Released: 18-Nov-2024 8:30 AM EST
Edible Bird's Nest-Infused Beverage: A New Weapon in the Fight Against Hypertension
Chinese Academy of Sciences

A recent study highlights the health benefits of a cocoa-flavored, soy-based powder drink mix enriched with hydrolysates from edible bird’s nests. This innovative functional beverage shows promise in managing hypertension and inflammation, along with improving glycemic control and prolonging satiety. The study focuses on the drink’s angiotensin-converting enzyme (ACE) inhibition and red blood cell membrane stabilization effects, suggesting a fresh approach to dietary management of chronic health issues.

   
Newswise: UTSW Epidemiologist to Receive AHA Distinguished Scientist Award
Released: 13-Nov-2024 2:05 PM EST
UTSW Epidemiologist to Receive AHA Distinguished Scientist Award
UT Southwestern Medical Center

Jiang He, M.D., Ph.D., Professor and Chair Designate of Epidemiology in the Peter O’Donnell Jr. School of Public Health at UT Southwestern Medical Center, is a 2024 recipient of the American Heart Association’s (AHA) highest commendation, the Distinguished Scientist award. The honor recognizes Dr. He’s prolific research on reducing the risks of cardiometabolic diseases, including heart disease, stroke, obesity, Type 2 diabetes, hypertension, dyslipidemia, and chronic kidney disease.

Released: 12-Nov-2024 10:20 AM EST
Researchers Suggest Stress Hormones Explain How Obesity Causes Diabetes
Rutgers University-New Brunswick

Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a Rutgers Health study.

Not for public release

This news release is embargoed until 7-Nov-2024 2:00 PM EST Released to reporters: 5-Nov-2024 9:25 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 7-Nov-2024 2:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 4-Nov-2024 3:20 PM EST
UW–Madison researchers find persistent problems with AI-assisted genomic studies
University of Wisconsin–Madison

University of Wisconsin–Madison researchers are warning that artificial intelligence tools gaining popularity in the fields of genetics and medicine can lead to flawed conclusions about the connection between genes and physical characteristics, including risk factors for diseases like diabetes.The faulty predictions are linked to researchers’ use of AI to assist genome-wide association studies.

Newswise: COVID-19 Sharply Boosts Risk for Blood-Fat Disorders
Released: 1-Nov-2024 9:40 AM EDT
COVID-19 Sharply Boosts Risk for Blood-Fat Disorders
Albert Einstein College of Medicine

A new study led by researchers at Albert Einstein College of Medicine involving more than 200,000 adults found that the COVID-19 pandemic caused a 29% increase in risk for developing dyslipidemia, a condition involving abnormal lipid (fat) levels in the blood. Seniors and people with type 2 diabetes were even more strongly affected, experiencing an approximately two-fold increased risk for developing dyslipidemia, which is a major risk factor for cardiovascular diseases such as heart attack and stroke. The research was published today in the print edition of The Journal of Clinical Investigation.

Released: 1-Nov-2024 7:45 AM EDT
Don’t Let Diabetes Dim Your Vision
American Society of Retina Specialists

During November’s Diabetic Eye Disease Awareness Month, the American Society of Retina Specialists encourages people with diabetes, their friends, and loved ones to learn more about diabetic retinopathy and diabetic macular edema and prioritize their eye health to protect and preserve vision.

28-Oct-2024 11:35 AM EDT
Sustained Remission of Diabetes and Other Obesity-Related Conditions Found a Decade After Weight Loss Surgery in Adolescence
Ann and Robert H. Lurie Children's Hospital of Chicago

Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 diabetes, high blood pressure and high cholesterol, according to the report published in the New England Journal of Medicine.

Released: 29-Oct-2024 6:25 PM EDT
Most Patients Can Continue Diabetes, Weight Loss GLP-1 Drugs Before Surgery, Those at Highest Risk for GI Problems Should Follow Liquid Diet Before Procedure
American Society of Anesthesiologists (ASA)

Most patients should continue taking their glucagon-like peptide-1 (GLP-1) receptor agonists before elective surgery, suggests new clinical guidance released by the American Society of Anesthesiologists (ASA), American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons. Patients at the highest risk for significant gastrointestinal (GI) side effects should follow a liquid diet for 24 hours before the procedure or other measures, depending on the specific circumstances.

24-Oct-2024 6:25 AM EDT
Think You’ve Outgrown Your High School Years? When It Comes To Drinking, A New Study Suggests Maybe Not
Research Society on Alcoholism

Adults aged 35 to 60 are drinking at unprecedented rates, with those who binge drank in high school reporting more past 30-day high-risk drinking in midlife. And this link may be especially strong for women, according to a study just published in Alcohol: Clinical and Experimental Research Health. These trends are particularly concerning as health conditions, and biological processes common with aging put adults in midlife at greater health risk from alcohol use.

   
18-Oct-2024 4:10 PM EDT
Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
American Society of Nephrology (ASN)

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

18-Oct-2024 3:35 PM EDT
Researchers Integrate Multiple Protein Markers to Predict Health Outcomes in Individuals with Chronic Kidney Disease
American Society of Nephrology (ASN)

Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.

18-Oct-2024 3:40 PM EDT
Heart and Kidney Outcomes After Canagliflozin Treatment in Older Adults
American Society of Nephrology (ASN)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.

18-Oct-2024 3:35 PM EDT
High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 1
American Society of Nephrology (ASN)

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

Not for public release

This news release is embargoed until 24-Oct-2024 7:00 AM EDT Released to reporters: 21-Oct-2024 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 24-Oct-2024 7:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.



close
2.80292